IRVINE, CA / ACCESSWIRE / October 19, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Investors, who purchased or otherwise acquired shares from June 17, 2015 through August 10, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 24, 2017 lead plaintiff motion deadline.
If you purchased shares of Dr. Reddy's during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
The Complaint alleges that, during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that it lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Following this news, shares of Dr. Reddy's lowered in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact:
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
SOURCE: Khang & Khang LLP
ReleaseID: 478297
